By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmalink AB 

Karlavägen 18

Stockholm    SE-102 49  Sweden
Phone: 46-0-8-505-66-312 Fax: 46-0-8-611-3303



Company News
Positive Results Of Phase IIb Clinical Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Published In The Lancet 3/29/2017 7:37:37 AM
Pharmalink AB Strengthens Board With Appointment Of Maria Carell As Chair 1/9/2017 11:48:46 AM
Pharmalink AB Announces European Orphan Drug Designation For Nefecon For Treatment Of Iga Nephropathy, An Inflammatory Kidney Disease 11/29/2016 9:47:50 AM
Pharmalink AB Raises SEK100m To Advance Nefecon Development As New Treatment For Kidney Disease 10/1/2015 6:11:56 AM
Pharmalink AB Phase II Trial Of Nefecon Halted Early 4/14/2015 6:15:40 AM
Pharmalink AB Acquires Novel Therapeutic Product Candidate For Treating Inflammation Associated With Osteoarthritis 3/18/2015 6:41:50 AM
Data From Clinical Study Of Pharmalink AB's Nefecon® To Be Presented At American Society Of Nephrology's Kidney Week 2014 11/3/2014 7:25:58 AM
Pharmalink AB Extends Patent Protection For Nefecon® Treatment For Renal Disease 10/27/2014 7:46:30 AM
Pharmalink AB Elects Bengt Julander As Chairman 10/14/2014 8:32:40 AM
Pharmalink AB's Core Patents For Nefecon® Treatment For Renal Disease Granted In United States, Europe, China And Hong Kong 7/10/2014 9:49:12 AM